Contrave Diet Pills Recommended. What's Next?

Contrave(R), a weight loss drug being developed by Orexigen(R) Therapeutics, Inc., was recommended by an expert panel of the FDA last week by a vote of 13-7. The vote surprised many who were expecting another defeat like those of lorcaserin and Qnesa earlier in the year.

There are questions about a possible link to cardiovascular issues, but the panel voted 11-8 to recommend that a study could be done post-approval, which could lead the way to FDA approval of Contrave(R) on January 31, 2011.

Orexigen(R) is also developing another weight loss product, Empatic(R), which may gain some attention and momentum from Contrave(R)'s approval.

Orexigen(R)'s stock zoomed from about $4.75 to more than $12.25 in after hous trading on the evening of the panel's decision, after trading had been halted for the day. On Wednesday, it floated back down to the $8-9 range where it has stayed, closing Friday at $8.43. With th possibility of approval in the fairly near future, the stock could see some interesting moves in the weeks ahead. For purposes of disclosure, I do not own any Orexigen(R) stock at the moment, though I could in the future.

Technorati Tags: Contrave™ naltrexone Diet Pills Weight Loss Pillsbupropion Diet Weight Loss Losing WeightEmpaticQnesalorcaserin

Weight Loss Pill CONTRAVE Gains Recommendation From FDA Panel

CONTRAVE has gained recommendation from the FDA's expert panel today by a vote of 13-7.

Orexigen's new entry into the weight loss arena gained the recommendation of the Food & Drug Administration's panel of experts this afternoon. Final approval will have to come from the FDA at a later time, but the FDA usually follows the lead of the panel.

More to come later.

Contrave Diet Pills

Contrave's Fate to be Decided by FDA Panel Dec 7

Contrave™ will have it's day on Tuesday, December 7 when an FDA panel of experts vote to approve it or send it back to the drawing board. The Food & Drug Administration released information on Friday sending mixed signals about Contrave™. The drug definitely helped users lose weight, but may not have reached the required FDA standards.

The FDA information also raised questions about potential side effects. Since two other weight loss drugs (Qnexa™and Lorcaserin™) failed to gain approval from the FDA panel of experts earlier this year and were not approved for use by the FDA, many experts are not too optimistic on Contrave™'s chances.

Here is a link to the FDA's recently published information on Contrave™ for the upcoming panel meeting. Orexigen Briefing Information for the December 7, 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee

Technorati Tags: Contrave™ naltrexone Diet Pills Weight Loss Pillsbupropion Diet Weight Loss Losing Weight